Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004

Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004–2014

Published:2024-03-25 Issue:4 Volume:47 Page:e32-e33
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Maltese Giuseppe¹²^ORCID,Sinclair Alan J.³

Affiliation:

1. 1Department of Diabetes and Endocrinology, Epsom and St. Helier University Hospitals, Surrey, U.K.

2. 2School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, U.K.

3. 3Foundation for Diabetes Research in Older People (fDROP), Droitwich Spa, London, U.K.

Publisher

American Diabetes Association

Link

https://diabetesjournals.org/care/article-pdf/47/4/e32/751803/dc232420.pdf

Reference5 articles.

1. Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes;Kutz;Diabetes Care,2023

2. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study;Malik;Lancet Healthy Longev,2023

3. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study;Goldman;Cardiovasc Diabetol,2023

4. Efficacy and safety of dulaglutide in older patients: a post hoc analysis of the REWIND trial;Riddle;J Clin Endocrinol Metab,2021

5. Metabolic impact of frailty changes diabetes trajectory;Sinclair;Metabolites,2023